Reversal of Dual Antiplatelet Therapy With Cold Stored Platelets
NCT ID: NCT03787927
Last Updated: 2020-07-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
60 participants
INTERVENTIONAL
2018-12-03
2021-12-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration
NCT00748371
Reversal of the Antiplatelet Effects of Ticagrelor in Combination With Aspirin, Using Normal Platelets
NCT03005704
The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack
NCT02144831
Aspirin in Patients With Myocardial Infarction and Thrombocytopenia
NCT00501345
Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets
NCT01744288
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
5 day CSP, then 5 day RTP
Participants will first complete collection and transfusion of 5 day autologous CSP (cold-stored platelet). Then they will complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.
The first 20 participants who complete the study will be randomized to this arm or '5 day RTP, then 5 day CSP.'
Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 5 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)
Autologous Platelet Transfusion (room-temperature-stored)
The participant will receive an autologous platelet transfusion of their room-temperature-stored platelets after 5 days of storage.
Autologous Platelet Transfusion (cold-stored 5 days)
The participant will receive an autologous platelet transfusion of their cold-stored platelets after 5 days of storage.
Aspirin
Aspirin (325mg) will be administered the day before every transfusion.
Clopidogrel
Clopidogrel (600mg) will be administered the day before every transfusion.
5 day RTP, then 5 day CSP
Participants will first complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). Then they will complete collection and transfusion of 5 day autologous CSP (cold-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.
The first 20 participants who complete the study will be randomized to this arm or '5 day CSP, then 5 day RTP.'
Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 5 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)
Autologous Platelet Transfusion (room-temperature-stored)
The participant will receive an autologous platelet transfusion of their room-temperature-stored platelets after 5 days of storage.
Autologous Platelet Transfusion (cold-stored 5 days)
The participant will receive an autologous platelet transfusion of their cold-stored platelets after 5 days of storage.
Aspirin
Aspirin (325mg) will be administered the day before every transfusion.
Clopidogrel
Clopidogrel (600mg) will be administered the day before every transfusion.
5 day RTP, then 10 day CSP
Participants will first complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). Then they will complete collection and transfusion of 10 day autologous CSP (cold-stored platelets).The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.
After the first 20 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 10 day CSP' and '10 day CSP, then 5 day RSP.'
Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 10 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)
Autologous Platelet Transfusion (room-temperature-stored)
The participant will receive an autologous platelet transfusion of their room-temperature-stored platelets after 5 days of storage.
Autologous Platelet Transfusion (cold-stored 10 days)
The participant will receive an autologous platelet transfusion of their cold-stored platelets after 10 days of storage.
Aspirin
Aspirin (325mg) will be administered the day before every transfusion.
Clopidogrel
Clopidogrel (600mg) will be administered the day before every transfusion.
5 day RTP, then 15 day CSP
Participants will first complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). Then they will complete collection and transfusion of 15 day autologous CSP (cold-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.
After the first 40 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 15 day CSP' and '15 day CSP, then 5 day RSP.'
Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 15 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)
Autologous Platelet Transfusion (room-temperature-stored)
The participant will receive an autologous platelet transfusion of their room-temperature-stored platelets after 5 days of storage.
Autologous Platelet Transfusion (cold-stored 15 days)
The participant will receive an autologous platelet transfusion of their cold-stored platelets after 15 days of storage.
Aspirin
Aspirin (325mg) will be administered the day before every transfusion.
Clopidogrel
Clopidogrel (600mg) will be administered the day before every transfusion.
10 day CSP, then 5 day RTP
Participants will first complete collection and transfusion of 10 day autologous CSP (cold-stored platelet). Then they will complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets).The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.
After the first 20 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 10 day CSP' and '10 day CSP, then 5 day RSP.'
Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 10 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)
Autologous Platelet Transfusion (room-temperature-stored)
The participant will receive an autologous platelet transfusion of their room-temperature-stored platelets after 5 days of storage.
Autologous Platelet Transfusion (cold-stored 10 days)
The participant will receive an autologous platelet transfusion of their cold-stored platelets after 10 days of storage.
Aspirin
Aspirin (325mg) will be administered the day before every transfusion.
Clopidogrel
Clopidogrel (600mg) will be administered the day before every transfusion.
15 day CSP, then 5 day RTP
Participants will first complete collection and transfusion of 15 day autologous CSP (cold-stored platelet). Then they will complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.
After the first 40 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 15 day CSP' and '15 day CSP, then 5 day RSP.'
Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 15 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)
Autologous Platelet Transfusion (room-temperature-stored)
The participant will receive an autologous platelet transfusion of their room-temperature-stored platelets after 5 days of storage.
Autologous Platelet Transfusion (cold-stored 15 days)
The participant will receive an autologous platelet transfusion of their cold-stored platelets after 15 days of storage.
Aspirin
Aspirin (325mg) will be administered the day before every transfusion.
Clopidogrel
Clopidogrel (600mg) will be administered the day before every transfusion.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Autologous Platelet Transfusion (room-temperature-stored)
The participant will receive an autologous platelet transfusion of their room-temperature-stored platelets after 5 days of storage.
Autologous Platelet Transfusion (cold-stored 5 days)
The participant will receive an autologous platelet transfusion of their cold-stored platelets after 5 days of storage.
Autologous Platelet Transfusion (cold-stored 10 days)
The participant will receive an autologous platelet transfusion of their cold-stored platelets after 10 days of storage.
Autologous Platelet Transfusion (cold-stored 15 days)
The participant will receive an autologous platelet transfusion of their cold-stored platelets after 15 days of storage.
Aspirin
Aspirin (325mg) will be administered the day before every transfusion.
Clopidogrel
Clopidogrel (600mg) will be administered the day before every transfusion.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Subject self-reports that he or she feels well and healthy
2. Subjects must be 18-59 years old, of either sex
3. Temperature: less than or equal to 99.5 F
4. Resting blood pressure: systolic less than or equal to 180 mmHg, diastolic less than or equal to100 mmHg
5. Resting heart rate: 40 to 100 beats per minute
6. Weight: greater than or equal to110 pounds,
7. Hematocrit: greater than or equal to 35 percent for females, greater than or equal to 38 percent for males, but not greater than 55 percent
8. Platelet count able to achieve target platelet yield per apheresis machine configuration parameters
9. Subjects must be able to read, understand and sign the informed consent document and commit to the study follow-up schedule. The ability to read and speak English is required for participation.
10. Subject must agree to avoid taking any aspirin or aspirin-containing drugs (e.g., Alka-Seltzer, Bufferin, Excedrin) or NSAIDs (e.g.,Feldene, Motrin, Aleve, Advil) or other drugs known to affect platelet function throughout their study participation.
11. Subjects must agree to avoid calcium channel blockers such as amlodipine (Norvasc), felodipine, and verapamil (Verelan, Calan) and proton pump inhibitors (PPIs) such as omeprazole (Prilosec), lansoprazole (Prevacid), esomeprazole (Nexium) and pantoprazole (Protonix) until all study blood draws are concluded. These classes of drugs may interfere with the action of clopidogrel and diminish its antiplatelet effect.
12. Subjects must have "good veins" for apheresis platelet collection and drawing blood samples.
13. Women of child bearing potential must agree to use an effective method of contraception during the course of the study. The following methods of contraception will be considered 'effective' when self-reported by subject; abstinence, intrauterine contraception devices, hormonal methods, barrier methods or history of sterilization.
14. Subject has phone and e-mail for contact and notification, and is able to come to the research site for approximately 9 visits over up to approximately 64 days.
Exclusion Criteria
1. Active acute infection or suspected active infection, temperature above 100 F or taking antibiotic
2. Active immune/inflammatory condition (e.g. gout, systemic lupus erythematosus, allograft rejection)
3. History of heart disease, including endorsement of shortness of breath with mild exertion (at the discretion of the PI).
4. History of significant liver, kidney, GI, blood, endocrine/metabolic, autoimmune or pulmonary disease, untreated hypertension and or metabolic syndrome (at the discretion of the PI).
5. Diabetes Mellitus
6. Cancer of any kind (exceptions being basal or squamous cell cancers of the skin), under treatment or resolved
7. History of bleeding events, family history of bleeding events, or known genetic disorder with bleeding diathesis
8. A family history of venous or arterial thrombosis before the age of 50 in first degree relatives
9. A personal history of DVT, venous or arterial thrombosis, blood clots or stroke
10. History of having been prescribed clopidogrel (Plavix), ticlopidine (Ticlid) or Ticagrelor (Brilinta).
11. Subject has taken any aspirin or aspirin-containing drugs (e.g., Alka-Seltzer, Bufferin, Excedrin) or NSAIDs (e.g.,Feldene, Motrin, Aleve, Advil) or other drugs known to affect platelet function within 14 days prior to screening.
12. Chronic NSAID therapy
13. Chronic steroid therapy
14. Known allergy to aspirin or clopidogrel
15. Subjects who are taking, or have taken within 14 days any of the following class of drugs protone pump inhibitors (PPIs) such as omeprazole, pantoprazole, lansoprazole, esomeprazole lipid lowering drugs/statins anticoagulants ACE-inhibitors phenytoine tolbutamide calcium channel blockers such as amlodipine, felodipine, verapamil
16. Current drug or alcohol dependence by subject's declaration.
17. Currently pregnant or nursing as assessed during interview. A urine pregnancy test prior to apheresis is required for women of childbearing potential.
18. Subject plans to participate in contact sports during study/observational period such as boxing, rugby, American football, soccer, or other risky recreational hobbies at the discretion of the investigator.
19. Unwilling or unable to comply with the protocol in the opinion of the investigator.
20. Participation in an experimental drug/device study within the past 30 days (other than this study). Subjects who have received an infusion on this study may not be re-enrolled.
21. Average initial (only for the first PFT) aggregation responses to ADP less than or equal to 60% by aggregometry platelet function testing.
22. Other unspecified reasons that, in the opinion of the Investigator, make the subject unsuitable for enrollment.
18 Years
59 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Blood Foundation
UNKNOWN
Bloodworks
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Moritz Stolla, MD
Role: PRINCIPAL_INVESTIGATOR
Bloodworks Northwest
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bloodworks Northwest Research Institute
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Miles J, Bailey SL, Obenaus AM, Mollica MY, Usaneerungrueng C, Byrne D, Fang L, Flynn JR, Corson J, Osborne B, Houck K, Wang Y, Shen Y, Fu X, Dong JF, Sniadecki NJ, Stolla M. Storage temperature determines platelet GPVI levels and function in mice and humans. Blood Adv. 2021 Oct 12;5(19):3839-3849. doi: 10.1182/bloodadvances.2021004692.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.